Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:11/25/2009)... 25 AMPAC Fine Chemicals LLC (AFC)...sdaq: APFC ) announced today that it received the...ward at the Annual Statewide Environmental Summit,...hnology Association (CMTA), the Industrial Environ... Council of California (CICC) held in San Diego. ...
(Date:11/25/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Mammography Equipment - A Global Marke.../p0164330/Mammography-Equipment---A-Global-Market-... cancer in industrialized as well as developing na...the mammography market. Globally, escalating aware...
(Date:11/25/2009)...PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: ...ping products for minimally disruptive surgical tr...ll host a conference call on Monday, November 30, ...nce call will focus on current issues relative to ...include comments from management followed by a sho...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2Consecos Four Major Offices Wrap Up Record Breaking United Way Campaign 59579 1Consecos Four Major Offices Wrap Up Record Breaking United Way Campaign 59579 2BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued its la...c data. It shows that the lethality of the virus ... the virus,s current outbreak in the spring of 200...(s.d. 0.1). The H1N1 infectivity count, however, r...n (PRWEB) November 27, 2009 -- Biotech firm Replik...
(Date:11/27/2009)...UR-SEINE, France, Nov. 27 Team Gar...cling team dedicated to ethical sporting and devel...nounced today that it will become Team Garmin-Tran...s a new sponsor of the team. Transitions Optical i...wear, offering the most advanced photochromic tech...
(Date:11/27/2009)...unprecedented medical, economic burdens, study pre...s) -- The number of people with diabetes in the Un... years, a new study predicts. , That would brin...ith the disease, up from 23.7 million today. , ,...h diabetes will triple, the study also warns, risi...
(Date:11/27/2009)... Specialist manufacturers who use medical load c...lions of dollars by bringing in technology partner...umbers of pro-active medical manufacturers are cal...tage of their projects, ensuring that progress wil...or potentially outdated technology. , ...
(Date:11/26/2009)... the number of Americans living with diabetes will...09 to 44.1 million in 2034. Over the same period, ...om $113 billion to $336 billion, even with no incr...ed at the University of Chicago report in the Dece...hose with diabetes covered by Medicare will rise f...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...rgery during the last 35 years at Johns Hopkins Un...// Charles J. Yeo, M.D., Samuel D. Gross Professor... of Thomas Jefferson University and Thomas Jeffers...ut of medicine may believe, major pancreatic cance...
...as revealed that variants of a sugar, is found to ... studies are still in ithe nascent stages, these f...manage Alzheimers and even offset the onslaught. ...isease. A treatment based on this, Scyllo-inositol...
...intestinal surgery, including stomach reduction fo...nt vitamin A deficiency//. The results of the stud...hthalmology. The researchers base their findi... patients had a family or personal history of eye ...
...o the long time mystery surrounding obesity patien...emory loss//. New Saint Louis University research ...eptin is a hormone secreted by fat cells that tell...d associate research professor in the division of ...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: